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Abstract Nucleoside diphosphate kinase (NDPK/nm23) ATP/ 
GDP phosphotransferase activity and serine autophosphoryla-
tion is inhibited by M-mbcAMP, 8-ClcAMP and 8-BrcAMP. 
Inhibition of the enzymatic activity largely depends on the 
concentration of ATP and becomes significant at ATP 
concentrations up to 0.5 mM and at effector concentrations 
measured in C6 cells stimulated with 1 mM cAMP analogue. N6-
mbcAMP is a substrate of the enzyme. DbcAMP and O'2-
mbcAMP, cAMP analogues with a modified 0'2-ribose, did not 
affect the NDPK activity. Cyclic AMP is only a moderate 
inhibitor of NDPK even at low ATP concentrations. Possible 
inhibitory effects of cAMP and cAMP analogues on reported 
extra- and intracellular functions of NDPK/nm23 are discussed. 
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1. Introduction 
Nucleoside diphosphate kinase (NDPK, EC 2.7.4.6) cata-
lyzes the transphosphorylation of a terminal phosphate of 
triphosphate nucleotides to nucleoside diphosphates. In higher 
eucaryotes two distinct polypeptide chains have been identi-
fied. The acidic NDPK-A (ß) and the basic NDPK-B (a) 
chain are encoded by the nm23-Hl and nm23-H2 genes, re-
spectively [1-5]. 
The enzyme is present in most tissues and is the main ex-
tramitochondrial enzyme involved in the conversion of GDP 
into GTP at the expense of ATP (reviewed in [6]). The enzyme 
acts by formation of an unstable phosphohistidine intermedi-
ate [7], but recently a stable serine phosphorylation has also 
been detected that is not involved in the phosphotransferase 
reaction [8,9]. NDPK is located in several cell compartments 
and has even been found associated with the cell surface, 
suggesting that it may have several distinct intra- and extra-
cellular functions. The enzyme may be functional in the GDP-
GTP conversion on GTP-binding proteins [10,11] and has 
been proposed to be involved in lymphocyte and neuroblas-
toma proliferation [12,13] and in the inhibition of myeloid 
leukemia differentiation [14]. In human breast carcinoma the 
expression of the nm23-Hl gene has been inversely related 
with the metastatic phenotype [15], has been correlated with 
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the inhibition of cell motility in response to serum, PDGF and 
IGF-I [16], and its overexpression leads to synthesis of base-
ment proteins and to growth arrest [17]. Serine autophosphor-
ylation of nm23-Hl has been related to its potential to sup-
press metastasis [9]. The nm23-H2 gene has been identified as 
the c-myc transcription factor PuF which does not require 
NDPK activity for its DNA binding [18]. These data clearly 
point to a function of the nm23 genes in the mechanism of cell 
proliferation and differentiation. 
In this communication we present evidence that the phos-
photransferase activity of NDPK/nm23 can be differentially 
inhibited intra- and extracellularly, and in normal and tumor-
al cells by some cAMP analogues. The inhibition by these 
effectors raises new perspectives on the elucidation of addi-
tional functions of NDPK/nm23 and on the use of cAMP 
analogues as anticancer agents. 
2. Materials and methods 
2.1. Materials 
Rat C6 glioma (ATCC no. CCL 107) was obtained from Flow 
Laboratories (UK) and maintained in monolayer culture as described 
[19]. Soybean trypsin inhibitor (STI), aprotinin, ATP, GDP, AMP, 
cAMP, dbcAMP, 0'2-mbcAMP, JV -^mbcAMP, and 8-BrcAMP were 
obtained from Sigma Chemical Co. (USA); [^32P]ATP, [ß-32P]GDP 
and 8-ClcAMP were from ICN Biomedicals (USA). 
2.2. NDPK phosphotransferase assay 
The standard NDPK phosphotransferase assay was performed in 
buffer A (50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM MgCl2), 
in the presence of different concentrations of ATP and GDP, and 0.1 
Ci/ml [γ-32Ρ]ΑΤΡ or [ß-32P]GDP as indicated in the figure legends. 
Incubation was at 37°C for 2.5, 5, 7.5 and 10 min. The reaction 
was stopped by addition of 50 mM EDTA, 1 μΐ of the assay mixture 
applied on a polyethyleneimine cellulose plate (Merck, Germany) and 
the nucleotides separated in 750 mM KH2PO4 (pH 3.65) by ascending 
chromatography. The radioactive spots were excised and counted. The 
reaction rates were calculated from the slope of the linear regression 
of the phosphotransfer at different time points. The standard devia-
tion on the reaction rate is the error on the slope. 
2.3. Serine autophosphorylation of NDPK 
Autophosphorylation was performed in buffer B (25 mM HEPES 
(pH 7.3), 140 mM NaCl, 1 mM MgCl2, 0.8 mM CaCl2, 5 mM KC1, 
5 mM EDTA) and in the presence of 20 nM fr32P]ATP (4500 Ci/ 
mmol). Incubation was at 37°C for 30 min. The reaction was stopped 
by addition of SDS-PAGE sample buffer to a final concentration of 
0.5% (w/v) SDS, 10% (v/v) glycerol, 0.5% (v/v) 2-mercaptoethanol, 
6 mM Tris-HCl (pH 6.8). After boiling of the samples for 5 min, 
they were analyzed by SDS-PAGE on a 20% (w/v) polyacrylamide 
gel. The gel was Coomassie stained (30 min in 0.1% (w/v) CBB-R250, 
7.5% (v/v) acetic acid, 40% (v/v) methanol) and destained for 16 h by 
successive washes in 10% (v/v) acetic acid, 40% (v/v) methanol. After 
dehydration in 50% ethanol the gel was dried and autoradiographed. 
2.4. Phosphoamino acid analysis 
Identification of the autophosphorylated residue was carried out 
using a modified procedure of Boyle et al. [20]. Briefly, NDPK was 
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autophosphorylated as described, separated by SDS-PAGE and 
blotted onto an Immobilon P membrane. The labelled NDPK was 
excised and hydrolyzed in 6 N HC1 at 110°C for 1 h. Two-dimensional 
phosphoamino acid analysis was performed by TLC. 
2.5. Purification of NDPK from C6 
C6 cells were grown in serum-free chemically defined medium [19]. 
The cells were harvested in 50 mM EDTA in PBS, homogenized in a 
Potter Elvejhem (30 strokes, 1000 rpm, 4°C) alternated by sonication 
(15 min, 4°C). The homogenization buffer contained 20 mM Tris-HCl 
(pH 7.2), 10 mM KC1, 1 mM EDTA, 20 μg/ml STI and 5 μΐ/ml 
aprotinin. The cell extract was dialyzed against 50 mM Tris-HCl 
(pH 7.1) and insoluble material removed by centrifugation at 
20000Xg for 30 min. The homogenate was successively applied on 
a heparin-Sepharose CL 6B (210 X10 mm; Pharmacia LKB, Sweden) 
and a DEAE-5PW column (75X7.5 mm; Waters, USA). Most 
NDPK was recovered from the flow through of both columns, of 
which the proteins were concentrated by binding to Bio-Gel-HTP 
hydroxyapatite (Bio-Rad Lab., USA) [19]. Further purification was 
by affinity chromatography on a cAMP-agarose column using a mod-
ified procedure of Weber et al. [21]. Briefly, the cyanogen bromide 
activated C-8 cAMP-agarose column (500X10 mm; Sigma Chemical 
Co., USA)) was equilibrated with starting buffer (SB) (50 mM Tris-
HCl (pH 7.5), 1 mM EDTA, 10% glycerol (w/v), 1 mM DTT). Aspe-
cifically bound proteins were removed by successive washing with SB 
containing 2 M NaCl and 1 mM AMP. NDPK was eluted with 1 mM 
cAMP in SB. The presence of NDPK in the different fractions was 
evaluated by immunoblotting using an NDPK-B antibody (CRS-B), 
kindly provided by Dr. M. Véron (Institut Pasteur, Paris). Cyclic 
AMP and EDTA were removed by binding to a Sep-Pak Light 
Waters Accell Plus QMA Cartridge (Waters, USA). 
3. Results 
NDPK is located in several cell compartments and has also 
been detected in the extracellular medium of cells [14]. We 
detected the presence of NDPK in C6 conditioned medium, 
in human bone marrow plasma and human sera (Willems, R., 
Van Bockstaele, D., and Siegers, H., unpublished data). 
The effect of cAMP analogues on NDPK activity has been 
investigated in the presence of different concentrations of 
ATP, e.g. 2 mM representing the physiological cellular con-
centration [22-26], 0.5 mM representative of some pathologi-
cal situations [22,23,27,28] and 0.5 μΜ representing the extra-
cellular ATP concentration in plasma and in the synaptic cleft 
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Fig. 1. Inhibition of the NDPK phosphotransferase activity by cAMP and cAMP analogues. (A) NDPK was assayed in the absence or pres-
ence of 1 mM of the indicated effector and in the presence of 2 mM ATP/50 μΜ GDP (0.1 mCi/ml [ß-32P]GDP), 0.5 mM ATP/50 μΜ GDP 
(0.1 mCi/ml [ß-32P]GDP), or 0.5 μΜ GDP/0.5 μΜ ATP (0.1 mCi/ml fr32P]ATP) as described in Section 2. Data are expressed as % activity. 
The reaction rate in the absence of effector is taken as 100%. C, control. (B) Autoradiograph of the TLC plate of assays in the presence of 0.5 
μΜ GDP/0.5 μΜ ATP, and in the absence (lane 1) or presence of 1 mM cAMP (lane 2), dbcAMP (lane 3), 0'2-mbcAMP (lane 4), N6-
mbcAMP (lane 5), 8-ClcAMP (lane 6), 8-BrcAMP (lane 7). A^-mbcAMP*, phosphorylated JV -^mbcAMP; O, origin. 
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Fig. 2. Inhibition of the NDPK phosphotransferase activity as a function of the concentration of JV -^mbcAMP and 8-ClcAMP. The phospho-
transferase activity of NDPK was determined in the presence of a varying concentration of JV -^mbcAMP (A) and 8-ClcAMP (B) as described 
in Section 2. ATP and GDP concentrations are as described in the legend to Fig. 1. Data are expressed as % activity. The reaction rate in the 
absence of effector is taken as 100%. 
[23,29-31]. The physiological cellular GDP level is reported to 
be 20 μΜ [25]. To avoid GDP inhibition of NDPK and its 
depletion within the reaction time used, a GDP working con-
centration of 50 μΜ seemed to be a reasonable estimate to 
represent the intracellular environment [32]. To our knowl-
edge, the GDP level in extracellular fluids has not been re-
ported and in the experiments using 0.5 μΜ ATP, an equi-
molar GDP concentration was used. 
In the presence of 2 mM ATP and 50 μΜ GDP and at an 
effector concentration of 1 mM, none of the assayed cAMP 
analogues induced inhibition of the ATP/GDP phosphotrans-
ferase activity greater than 40% (Fig. 1). However, when the 
ATP concentration was lowered to 0.5 mM the inhibition by 
1 mM Jv^-mbcAMP, 8-ClcAMP and 8-BrcAMP already in-
creased to 40, 50 and 60%, respectively. At 0.5 μΜ ATP the 
inhibition by the former effectors increased to more than 80% 
and also cAMP inhibited the NDPK ATP/GDP phospho-
transferase reaction by 50%. DbcAMP and 0'2-mbcAMP 
did not affect the NDPK activity under all conditions assayed 
(Fig. 1). At 0.5 μΜ ATP JV^-mbcAMP was a more potent 
inhibitor than 8-ClcAMP, e.g. the concentration of effector 
resulting in 50% inhibition (I50) was 50 and 200 μΜ for N
6-
mbcAMP and 8-ClcAMP, respectively. On the other hand, at 
0.5 and 2 mM ATP, the inhibition of JV^-mbcAMP was lower 
than those of 8-ClcAMP (Fig. 2A). Analysis by TLC of the 
reaction mixtures at low ATP/GDP concentrations demon-
strated that A^-mbcAMP is a substrate of NDPK and be-
comes phosphorylated in the enzymatic reaction (Fig. 2B). 
NDPK autophosphorylation assays were performed in the 
absence of GDP. The latter induces rapid dephosphorylation 
of the autophosphorylated intermediate. In the absence of 
GDP and in the presence of EDTA a stable serine phosphoen-
zyme intermediate was obtained. This autophosphorylation 
can be inhibited by those cAMP analogues which are also 
able to inhibit the phosphotransferase activity (Fig. 3B). 
4. Discussion 
Cyclic AMP is implicated in the regulation of cell growth 
and differentiation by activation of two isoforms of PKA, e.g. 
PKA-I which relates to cell proliferation and PKA-II primar-
ily involved in differentiation [33]. Chloro cAMP, a strong 
growth inhibitor of cancer cells in culture and in vivo [34-
37], has been proposed to restore the normal balance of the 
PKA isoforms in tumor cells and has been included in pre-
clinical trials I/II for the treatment of human breast cancers 
[38]. 
In this communication we present evidence that NDPK/ 
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Fig. 3. Autophosphorylation of NDPK and its inhibition by cAMP 
and cAMP analogues. (A) Identification of the phosphorylated ami-
no acid. The acid- and heat-stable phosphoamino acid was identified 
by two-dimensional TLC. Phosphotyrosine, -threonine and -serine 
markers were added to the sample before TLC separation. (B) 
NDPK autophosphorylation was performed as described in Section 
2 in the presence of the indicated concentration of effector. The 
autoradiographs shown are representative of at least two independ-
ent experiments. 
nm23 is an additional target of cAMP analogues and may be 
involved in the growth inhibition of cancer cells. 
Inhibition of erythrocyte NDPK by cAMP has already been 
described by Mourad and Parks [39]. More recently, crystal-
lographic data of the cAMP-NDPK complex have been re-
ported indicating a possible physiological function for the 
cAMP-mediated inhibition of NDPK [40]. We have evaluated 
the effect of cAMP and cAMP analogues on the NDPK ATP/ 
GDP phosphotransferase activity and its autophosphorylation 
at ATP concentrations approximating the concentration in 
normal (2 mM) and tumoral (0.5 mM) cells and approximat-
ing the extracellular concentration (0.5 μΜ). Cyclic AMP was 
only a weak inhibitor of the NDPK phosphotransferase ac-
tivity with an 750 of approx. 1 mM at an ATP concentration 
of 0.5 μΜ. In comparison, the cAMP analogues 8-ClcAMP, 
8-BrcAMP and A^-mbcAMP were more efficient effectors and 
inhibited the NDPK activity by more than 80% at an ATP 
concentration of 0.5 μΜ. Under the latter conditions, an Im 
of approx. 50 and 200 μΜ has been measured for N6-
mbcAMP and 8-ClcAMP, respectively. The presented data 
demonstrate that the extracellular NDPK activity detected 
in sera and conditioned medium of cells can be completely 
inhibited by the former cAMP analogues. Furthermore, in 
tumor cells the intracellular NDPK activity can also be inhib-
ited taking into account: (i) an intracellular concentration of 
A^-mbcAMP and 8-ClcAMP in the millimolar range, e.g. 18.0 
and 10.6 fmol/cell (1.6 ul/106cells), respectively, after stimula-
tion of rat C6 glioma for 48 h with 1 mM effector ([41], 
Anciaux, K., Van Dommelen, K., Nicolai, S., Van Mechelen, 
E. and Siegers, H. unpublished data); and (ii) a reduction of 
the intracellular ATP concentration in tumor cells by 30-70% 
[22,23]. A^-mbcAMP is a substrate of the enzyme and as such 
a competitive inhibitor of NDPK. DbcAMP and O'2-
mbcAMP did not affect the NDPK phosphotransferase activ-
ity. However, in rat C6 glioma dbcAMP is able to increase the 
intracellular concentration of cAMP to 0.6 mM, resulting in 
moderate inhibition of NDPK [42]. Based on crystallographic 
data, Strelkov et al. [40] proposed a competition between ATP 
and cAMP for binding in the active site of the enzyme. Cyclic 
AMP binds in the catalytic cleft mainly by its ribose moiety. 
The O'2 atom of the latter interacts with He111 [40] indicating 
that cAMP analogues with a modified O'2 atom like dbcAMP 
and 0'2-mbcAMP are unable to bind in the active site of 
NDPK. 
Besides its phosphotransferase activity involving a phos-
phohistidine intermediate, NDPK can be autophosphorylated 
on a serine [43]. The latter autophosphorylation is low in 
comparison with the histidine phosphorylation [43,44] but 
has been inversely related to the potential of NDPK-A/ 
nm23-Hl to suppress metastasis [9]. In order of potency, the 
autophosphorylation of NDPK is inhibited by A^-mbcAMP, 
8-ClcAMP and cAMP and closely parallels the inhibition of 
the phosphotransferase activity. 
The fact that cAMP can bind to NDPK but is only a weak 
inhibitor of its phosphotransferase activity and autophosphor-
ylation suggests that other activities are probably regulated by 
cAMP, e.g. its transcription factor (PuF) activity for the c-
myc gene [18]. Although inhibition by cAMP and cAMP ana-
logues of the latter transcriptional activity remains to be de-
termined, the presented data demonstrated that effectors like 
A^-mbcAMP and 8-ClcAMP can be used to elucidate the still 
unknown extra- and intracellular function(s) of NDPK/nm23. 
In addition, the differential inhibition of NDPK by 8-
ClcAMP as a result of the ATP difference in normal and 
tumoral cells may provide new perspectives on its use as an 
anticancer agent [34,37]. 
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